IDH1 and central nervous system cancer: The activating mutation is associated with 1p/19q codeletion and oligodendroglial histology in the presence of IDH1 mutation and identifies a subset of aggressive astrocytic tumors lacking IDH1 mutation, highlighting its potential diagnostic and prognostic impact in lower-grade gliomas [19, 20, 23, 25, 26].